bluuebunny/crossref_metadata_2025_split huggingface dataset:
Recurrent acute myocarditis: An under-recognized clinical entity associated with the later diagnosis of a genetic arrhythmogenic cardiomyopathy
Authors: Ollitrault Pierre , Al Khoury Mayane , Troadec Yann , Calcagno Yoann , Champ-Rigot Laure , Ferchaud Virginie , Pellissier Arnaud , Legallois Damien , Milliez Paul , Labombarda Fabien 
Published: October 2022

BackgroundMyocardial inflammation has been consistently associated with genetic arrhythmogenic cardiomyopathy (ACM) and it has been hypothesized that episodes mimicking acute myocarditis (AM) could represent early inflammatory phases of the disease.ObjectiveWe evaluated the temporal association between recurrent acute myocarditis (RAM) episodes and the later diagnosis of a genetic ACM.Materials and methodsBetween January 2012 and December 2021, patients with RAM and no previous cardiomyopathy were included (Recurrent Acute Myocarditis Registry, NCT04589156). A follow-up visit including clinical evaluation, resting and stress electrocardiogram, cardiac magnetic resonance imaging, and genetic testing was carried out. Endpoints of the study was the incidence of both ACM diagnosis criteria and ACM genetic mutation at the end of follow-up.ResultsTwenty-one patients with RAM were included and follow-up was completed in 19/21 patients (90%). At the end of follow-up, 3.3 ± 2.9 years after the last AM episode, 14/21 (67%) patients with an ACM phenotype (biventricular: 10/14, 71%; left ventricular: 4/14, 29%) underwent genetic testing. A pathogenic or likely pathogenic mutation was found in 8/14 patients (57%), 5/8 in the Desmoplakin gene, 2/8 in the Plakophillin-2 gene, and 1/8 in the Titin gene. Family history of cardiomyopathy or early sudden cardiac death had a positive predictive value of 88% for the presence of an underlying genetic mutation in patients with RAM.ConclusionRAM is a rare entity associated with the latter diagnosis of an ACM genetic mutation in more than a third of the cases. In those patients, RAM episodes represent early inflammatory phases of the disease. Including RAM episodes in ACM diagnosis criteria might allow early diagnosis and potential therapeutic interventions.
Energy management of renewable energy-based microgrid system with HESS for various operation modes
Authors: Kumar G. V. Brahmendra , Palanisamy K. 
Published: October 2022

This paper proposes a ramp-rate control approach for a grid-connected MG with a hybrid energy storage system. Distributed energy sources (DERs), such as solar photovoltaic (PV) and wind, combined with energy storage (ES) and controllable loads, are critical to a power grid that can handle the intermittent nature of renewable energy sources. Therefore, the complexity of the system is increasing as researchers move towards a more renewable based power grid. An energy management system (EMS) for microgrids must consider the power available in RESs as well as the storage capacity of energy storage devices (ESSs). Modern MGs include a wide range of converters for a variety of applications, including distributed generation interconnection, grid integration, energy storage management systems, and demand management, among others. So, the ramp-rate control smooths fluctuations in photovoltaic power, which increases system reliability. In the proposed system, 80 V DC is used to supply high and low power DC loads. The suggested system can extract the maximum amount of energy from RESs, maintain efficient ESS management, and achieves quick DC-link voltage regulation with settling time of 230 ms throughout all operating modes. These conditions are met by the energy management system, which gives the MG with operational capability and ensures its reliability. The MG with proposed features and EMS was validated using the MATLAB/Simulink environment, and results were obtained using the Hardware-in-the-Loop (HIL) experimental test bench. The proposed small-scale RES-based MG can be used to develop and test algorithms for a wide range of MG applications.
Transport of montmorillonite colloid in unsaturated packed column: The combined effects of sand grain size, flow rate and colloid concentration
Authors: Zhang Linlin , Zhu Jun , Zhang Qiulan , Shao Jingli , Cui Yali , Zhang Aiming 
Published: October 2022

The transport of colloid in unsaturated porous media affects the migration of contaminants and thus is closely related to groundwater resources protection. To figure out the combined effects of grain size, colloid concentration and injection flow rate on montmorillonite colloid transport characteristics in unsaturated quartz sand, a total of 27 sets of column experiments were conducted with three kinds of quartz sand (20, 40, 60 mesh), three flow rates (1.98, 3.96, 5.94 cm3/min) and three colloid concentrations (300, 600, 900 mg/L), using three packed columns with the inner diameter of 11 cm and the height of 40 cm. The experimental results showed that the transport of Na-montmorillonite colloid particles in the unsaturated quartz sand columnoccurred with significant retention. In the 20 mesh quartz sand column, the average peak values of the penetration curves for low and high concentration colloidal solutions of 300 and 900 mg/L increased by 44% and 27%, respectively, as the flow rate increased from 1.98 to 5.94 cm3/min. The average peak value of the colloidal solution with concentration 300 mg/L increased 17% more than that of the colloidal solution with 900 mg/L for increasing flow rate. When the injection flow rate of the colloidal solution was increased from 1.98 to 5.94 cm3/min, the effect of flow rate on colloidal transport was the most obvious, followed by the effect of media particle size, while the effect of colloidal solution concentration was the least. The calculation based on the total potential energy of Derjaguin-Landau-Verwey-Overbeek (DLVO) and collision efficiency further explained the retention of colloids in unsaturated porous media.
Knowledge mapping of the links between the microbiota and allergic diseases: A bibliometric analysis (2002–2021)
Authors: Lv Hao , Wang Yunfei , Gao Ziang , Liu Peiqiang , Qin Danxue , Hua Qingquan , Xu Yu 
Published: October 2022

BackgroundIn recent decades, dramatic changes in modern environmental exposures and lifestyles have resulted in a steep rise in the prevalence of allergic diseases such as asthma, allergic rhinitis, atopic dermatitis and food allergies. Evidence is mounting that the microbiota plays a crucial role in allergic disorder development and evolution. Therefore, a better understanding of allergic diseases within the context of the microbiota is urgently needed. This work aimed to comprehensively outline general characteristics, research hotspots, evolution routes, and emerging trends in this area.MethodsRelevant publications from January 2002 to December 2021 were obtained from the Web of Science Core Collection on 5 August 2022. Bibliometric and visual analyses were performed using CiteSpace; VOSviewer; an online bibliometric platform; and Microsoft Excel 2019.ResultsIn total, 2535 documents met the requirements. The annual number of publications has shown rapid growth in the last two decades. The USA, University of California System, and Isolauri E of the University of Turku were the most productive and influential country, institution, and author, respectively. The Journal of Allergy and Clinical Immunology was the most prolific and most cocited journal. High-frequency keywords included “gut microbiota”, “asthma”, “atopic dermatitis”, “children”, and “probiotics”. Recent studies have focused on “atopic dermatitis”, “skin”, “asthma”, and “probiotics”, according to the cocitation analysis of references. Burst detection analysis of keywords showed that “community”, “skin microbiome”, “microbiome”, “Staphylococcus aureus”, and “chain fatty acid” were emerging research frontiers, which currently have ongoing bursts.ConclusionIn the last 20 years, studies of the microbiota in allergic diseases have been flourishing, and the themes have been increasing in depth. These findings provide valuable references on the current research hotspots and gaps and development trends in the link between the microbiota and allergic diseases.
The observation of anterior segment in children with an R124L mutation corneal dystrophy by anterior segment optical coherence tomography and in vivo confocal microscopy
Authors: Fu Mengjun , Zhao Jing , Zhang Haorun , Wang Rui , Zhou Xingtao 
Published: October 2022

PurposeTo evaluate the anterior segment in children with an R124L mutation corneal dystrophy (CD) using anterior segment optical coherence tomography (AS-OCT) and in vivo confocal microscopy (IVCM).MethodsWe investigated a family with prevalent CD and an R124L mutation; 59 individuals (14 patients; 6 male and 8 female, aged 2–69 years, 6 children, 2:4 male: female ratio) from four generations were included. We observed corneal lesions through ophthalmologic examinations, AS-OCT, and IVCM. The mean follow-up was 4.60 ± 3.91 years.ResultsThe mean age for childhood CD onset was 0.90 ± 0.61 years. An Avelino DNA test revealed a heterozygous R124L mutation. Clinical manifestations included recurrent photophobia, tearing, and a foreign body sensation. Recurrence frequency decreased with age. Slit lamp microscopy revealed a rough corneal epithelium. The anterior matrix under the corneal epithelium and the anterior elastic layer were scattered with gray and white opacity. From onset to follow-up, the children’s visual acuity decreased from 0.34 ± 0.12 to 0.55 ± 0.17 LogMAR units. AS-OCT showed uneven corneal epithelial thickness. The Bowman’s layer was replaced by abnormal substances in the anterior segment. Corneal deposits became increasingly thicker; the average thickness at the last follow-up was 102.78 ± 10.13 μm. IVCM revealed uneven and reflective signals in the corneal upper cortex and subepithelium, with unclear boundaries and a loss of normal cell morphology.ConclusionWe report an early age of onset in a family with prevalent CD due to R124L mutations. AS-OCT is a convenient, quick, and non-contact tool for screening and monitoring the pathological process of CD.
Systematic assessment of clinical and bacteriological markers for tuberculosis reveals discordance and inaccuracy of symptom-based diagnosis for treatment response monitoring
Authors: Mtafya Bariki , Sabi Issa , John Joseph , Sichone Emanuel , Olomi Wilyhelmina , Gillespie Stephen H. , Ntinginya Nyanda E. , Sabiiti Wilber 
Published: October 2022

BackgroundClinical symptoms are the benchmark of tuberculosis (TB) diagnosis and monitoring of treatment response but are not clear how they relate to TB bacteriology, particularly the novel tuberculosis-molecular bacterial load assay (TB-MBLA).MethodsPresumptive cases were bacteriologically confirmed for TB and assessed for symptoms and bacteriological resolution using smear microscopy (SM), culture, and TB-MBLA over 6-month treatment course. Kaplan–Meier and Kappa statistics were used to test the relationship between symptoms and bacteriological positivity.ResultsA cohort of 46 bacteriologically confirmed TB cases were analyzed for treatment response over a 6-month treatment course. Pre-treatment symptoms and bacteriological positivity concurred in over 70% of the cases. This agreement was lost in over 50% of cases whose chest pain, night sweat, and loss of appetite had resolved by week 2 of treatment. Cough resolved at a 3.2% rate weekly and was 0.3% slower than the combined bacteriological (average of MGIT and TB-MBLA positivity) resolution rate, 3.5% per week. A decrease in TB-MBLA positivity reflected a fall in bacillary load, 5.7 ± 1.3- at baseline to 0.30 ± 1.0- log10 eCFU/ml at month 6, and closer to cough resolution than other bacteriological measures, accounting for the only one bacteriologically positive case out of seven still coughing at month 6. Low baseline bacillary load patients were more likely to be bacteriologically negative, HR 5.6, p = 0.003 and HR 3.2, p = 0.014 by months 2 and 6 of treatment, respectively.ConclusionThe probability of clinical symptoms reflecting bacteriological positivity weakens as the patient progresses on anti-TB therapy, making the symptom-based diagnosis a less reliable marker of treatment response.
The effect of Baduanjin on the balancing ability of older adults: A systematic review and meta-analysis
Authors: Guo Linxuan , Liu Zhihao , Yuan Wenxue 
Published: October 2022

PurposeTo systematically evaluate the effect of Baduanjin on the balancing ability of older adults.MethodsThe systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Six electronic databases were searched for eligible studies. Data synthesis and statistical analysis using a random effects model were performed with Review Manager 5.4. Random-effects weights were used to pool the effect sizes. Publication bias was assessed by funnel plot.ResultsA total of 17 RCTs involving 1,267 patients were identified. The meta-analysis showed that the Baduanjin group was significantly superior to the control group in balancing performance measured by Berg balance scale [mean difference (MD) 4.82; 95% confidence interval (CI) 3.40 to 6.24, P &lt; 0.00001], Timed Up and Go (MD −2.21, 95% CI −2.69 to −1.74, P &lt; 0.00001) and Eye Closed One Leg Standing Balance (MD 2.01, 95% CI 0.79 to 3.23, P &lt; 0.00001) tests.ConclusionBaduanjin can effectively affect the balancing ability of older adults. More high-quality evidence-based studies are required to confirm these findings.Systematic review registration[https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=293183], identifier [CRD42021293183].
Plasma-derived phosphoglycerate mutase 5 as a biomarker for Parkinson’s disease
Authors: Feng Liang , He Haijun , Xiong Xi , Xia Kai , Qian Shuangjie , Ye Qianqian , Feng Feifei , Zhou Shuoting , Hong Xianchai , Liu Yiming , Xie Chenglong 
Published: October 2022

BackgroundWe aimed to examine whether plasma-derived phosphoglycerate mutase 5 (PGAM5) can be a biomarker for Parkinson’s disease (PD) diagnosis as well as its association with the severity of motor/non-motor manifestations of PD.MethodsWe enrolled 124 patients with PD (PD group) and 50 healthy controls (HC group). We measured plasma PGAM5 levels using a quantitative sandwich enzyme immunoassay. Patients with PD underwent baseline evaluations using the Unified Parkinson’s Disease Rating Scale (UPDRS), while participants in both groups were evaluated using scales for non-motor manifestations. Receiver operating characteristic curves were used to evaluate the predictive utility of plasma PAMG5 alone and combined with other factors.ResultsPlasma PAMG5 levels were significantly higher in the PD group; the area under the curve (AUC) of plasma PGAM5 levels alone was 0.76. The AUC values for elderly participants and patients without hypertension were 0.78 and that for was 0.79. Notably, plasma PGAM5 levels combined with plasma oligomeric α-synuclein (α-syn) and the score of the REM sleep behavior disorder questionnaire-Hong Kong (RBDQ-HK) showed AUC values of 0.80 and 0.82. Multivariable logistic analysis revealed that plasma PAMG5 levels were independently associated with PD (odds ratio,1.875 [95% confidence interval 1.206–2.916], p = 0.005) but not the severity of motor/non-motor manifestations of PD.ConclusionPlasma PGAM5 is an independent biomarker for PD, especially among elderly patients (age &gt; 60 years) and patients without hypertension. The predictive utility of PGAM5 was improved when combined with plasma oligomeric α-syn or the RBDQ-HK score.
Diffusion-weighted imaging-based radiomics for predicting 1-year ischemic stroke recurrence
Authors: Wang Hao , Sun Yi , Zhu Jie , Zhuang Yuzhong , Song Bin 
Published: October 2022

PurposeTo investigate radiomics based on DWI (diffusion-weighted imaging) for predicting 1-year ischemic stroke recurrence.MethodsA total of 1,580 ischemic stroke patients were enrolled in this retrospective study conducted from January 2018 to April 2021. Demographic and clinical characteristics were compared between recurrence and non-recurrence groups. On DWI, lesions were segmented using a 2D U-Net automatic segmentation network. Further, radiomics feature extraction was done using the segmented mask matrix on DWI and the corresponding ADC map. Additionally, radiomics features were extracted. The study participants were divided into a training cohort (n = 157, 57 recurrence patients, and 100 non-recurrence patients) and a test cohort (n = 846, 28 recurrence patients, 818 non-recurrence patients). A sparse representation feature selection model was performed to select features. Further classification was accomplished using a recurrent neural network (RNN). The area under the receiver operating characteristic curve values was obtained for model performance.ResultsA total of 1,003 ischemic stroke patients (682 men and 321 women; mean age: 65.90 ± 12.44 years) were included in the final analysis. About 85 patients (8.5%) recurred in 1 year, and patients in the recurrence group were older than the non-recurrence group (P = 0.003). The stroke subtype was significantly different between recurrence and non-recurrence groups, and cardioembolic stroke (11.3%) and large artery atherosclerosis patients (10.3%) showed a higher recurrence percentage (P = 0.005). Secondary prevention after discharge (statins, antiplatelets, and anticoagulants) was found significantly different between the two groups (P = 0.004). The area under the curve (AUC) of clinical-based model and radiomics-based model were 0.675 (95% CI: 0.643–0.707) and 0.779 (95% CI: 0.750–0.807), respectively. With an AUC of 0.847 (95% CI: 0.821–0.870), the model that combined clinical and radiomic characteristics performed better.ConclusionDWI-based radiomics could help to predict 1-year ischemic stroke recurrence.
Stroke services in the Middle East and adjacent region: A survey of 34 hospital-based stroke services
Authors: Al Hashmi Amal. M. , Shuaib Ashfaq , Imam Yahia , Amr Dareen , Humaidan Hani , Al Nidawi Firas , Sarhan Ahmed , Mustafa Wessam , Khalefa Wael , Ramadan Ismail , Usman Fritz Sumantri , Hokmabadi Elyar Sadeghi , Ghorbani Mohammed , Nassir Temeem , Aladham Farid , Salmeen Athari , Kikano Raghid , Muda Sobri , Jose Sachin , Bulushi Manal Al , Sajwani Badrai , Wasay Mohammad , Bashir Qasim , Al Hazzani Adel , Khoja Waleed , Alkadere Radwan , Osman Haytham , Hussein Abbashar , Churojana Anchalee , Hammami Nadia , Ozdemir Atilla Ozcan , Giray Semih , Gurkas Erdem , Hussain Seyd Irteza , Sallam Abdul Rahman , Mansour Ossama Yassin 
Published: October 2022

BackgroundAcute stroke care is complex and requires multidisciplinary networking. There are insufficient data on stroke care in the Middle East and adjacent regions in Asia and Africa.ObjectiveEvaluate the state of readiness of stroke programs in the Middle East North Africa and surrounding regions (MENA+) to treat acute stroke.MethodOnline questionnaire survey on the evaluation of stroke care across hospitals of MENA+ region between April 2021 and January 2022.ResultsThe survey was completed by 34/50 (68%) hospitals. The median population serviced by participating hospitals was 2 million. The median admission of patients with stroke/year was 600 (250–1,100). The median length of stay at the stroke units was 5 days. 34/34 (100%) of these hospitals have 24/7 CT head available. 17/34 (50%) have emergency guidelines for prehospital acute stroke care. Mechanical thrombectomy with/without IVT was available in 24/34 (70.6%). 51% was the median (IQR; 15–75%) of patients treated with IVT within 60 min from arrival. Thirty-five minutes were the median time to reverse warfarin-associated ICH.ConclusionThis is the first large study on the availability of resources for the management of acute stroke in the MENA+ region. We noted the disparity in stroke care between high-income and low-income countries. Concerted efforts are required to improve stroke care in low-income countries. Accreditation of stroke programs in the region will be helpful.
The mobile sleep medicine model in neurologic practice: Rationale and application
Authors: Boulos Mark I. , Chi Luqi , Chernyshev Oleg Y. 
Published: October 2022

BackgroundUndiagnosed obstructive sleep apnea (OSA) is prevalent in neurological practice and significantly contributes to morbidity and mortality. OSA is prevalent in US adults and causes poor quality sleep and significant neurocognitive, cardiovascular, and cerebrovascular impairments. Timely treatment of OSA reduces cardio-cerebrovascular risks and improves quality of life. However, most of the US population has limited systematic access to sleep medicine care despite its clinical significance.FocusWe discuss the importance of systematic screening, testing, and best-practice management of OSA and hypoventilation/hypoxemia syndromes (HHS) in patients with stroke, neurocognitive impairment, and neuromuscular conditions. This review aims to introduce and describe a novel integrated Mobile Sleep Medicine (iMSM) care model and provide the rationale for using an iMSM in general neurological practice to assist with systematic screening, testing and best-practice management of OSA, HHS, and potentially other sleep conditions.Key pointsThe iMSM is an innovative, patient-centered, clinical outcome-based program that uses a Mobile Sleep Medicine Unit—a “sleep lab on wheels”—designed to improve access to OSA management and sleep care at all levels of health care system. The protocol for the iMSM care model includes three levels of operations to provide effective and efficient OSA screening, timely testing/treatment plans, and coordination of further sleep medicine care follow-up. The iMSM care model prioritizes effective, efficient, and patient-centered sleep medicine care; therefore, all parties and segments of care that receive and provide clinical sleep medicine services may benefit from adopting this innovative approach.